Search Results

In June 2020, in accordance with the 21st Century Cures Act of 2016 and the Prescription Drug User Fee Act (PDUFA), the U.S. Food and Drug Administration (FDA) launched Project Patient Voice. This patient-focused drug development initiative facilitates systematic approaches to collecting and using meaningful patient and caregiver input, to better inform medical product development and regulatory decision-making, taking the use of real-world evidence (RWE) to a new level.

The Arthritis Foundation, Trio Health (Trio), and American Rheumatology Network (ARN) announce a collaboration to collectively respond to the patient voice as reported in both the Arthritis Foundation’s Live Yes! INSIGHTS study and Trio-ARN’s clinical insights from more than 370,000 rheumatology patients.

American Rheumatology Network (ARN), in partnership with Trio Health, launched ARN Clinical Research to transform drug development for rheumatology research. This technology-driven solution will unite the power of the ARN network with Trio’s proven data management technologies to develop a real-time integrated platform enabling manufacturers to rapidly achieve their goals.

Michael Cooper, CEO of American Rheumatology Network   We are pleased to announce we have appointed Michael Cooper as American Rheumatology Network’s (ARN) new CEO, effective immediately. Michael’s appointment reflects ARN’s current state: enthusiastic and ready to take on the future after another strong year of growth and success. We are excited for Michael to guide our company using his unique experience in distribution and group purchasing organizations. There is enormous opportunity for ARN that lies ahead, and we could not be happier with Michael joining our family and helping our network achieve continued success. Michael is an effective healthcare

Each patient is unique. What if their treatment path was too? That possibility is at the core of precision medicine. J. Eugene Huffstutter, MD Precision medicine allows patients to receive treatment based on their personal, genetic makeup. It is commonly associated with oncology, where therapies can address patients’ genetic biomarkers rather than just the location of their tumor. This personalized approach has already improved cancer care. Now, it has the potential to change how other diseases are treated too. Click to read full article

Trio Health, a leading technology provider of real-world data and insights on patients announces the launch of the first-ever Patient Voice database in Rheumatology to acknowledge and incorporate the voice of the patient in access programs, clinical development, and brand team care management programs.

The ARN-Trio registry recently hosted a webinar unlocking deep insights into the “Why” behind patients discontinuing prescription therapy. The recorded webinar is available here. ARN-Trio registry uniquely employs trained chart abstractors to review unstructured data for the 369,000 patients in the registry, identifying the actual reasons for discontinuations as recorded in the visit notes. Traditionally, this information has not been available for analysis as it is not recorded in structured data fields. The results are paradigm-changing, revealing that 86% of treatment discontinuations are associated with symptoms, and only 36% with efficacy (overlap occurs). This is startling, that in a specialty